Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.922
Filtrar
2.
Medicine (Baltimore) ; 100(12): e24816, 2021 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-33761642

RESUMEN

ABSTRACT: Antihypertensive drugs have been of significant interest to the pharmaceutical industry due to increasing sales opportunities in a global market. The financial relationships between pharmaceutical companies and the Japanese Society of Hypertension (JSH) have a possible influence on clinical practices in Japan. This study examined the distribution of pharmaceutical payments made to the authors of the revised Guidelines for the Management of Hypertension (JSH2019) and the transparency of the Conflict of Interest disclosure that each author made.We retrospectively obtained publicly available data regarding payments made by Japanese pharmaceutical companies to all authors of the JSH2019 in 2016. We also collected data on individual financial disclosure of JSH2019 authors to investigate whether their self-reported financial relationship with companies were compliant to the financial disclosure policy of JSH2019.The total and mean payment values reported by pharmaceutical companies were $4,246,436 and $21,447, respectively. Of the 198 authors, 171 (86.4%) authors received at least 1 payment. Of 74 authors required to disclose their conflict of interest (COI) the authors, one-third failed to follow the COI policy covering the clinical guidelines.Major pharmaceutical companies selling antihypertensive drug products in the Japanese market had a significant financial connection with the JSH2019 authors. Financial relationships between pharmaceutical companies and authors or Japanese medical societies are raising significant concerns about the credibility of clinical guidelines and the potentially biases and undue influences that they may cause, especially with respect to adverse prescription patterns.


Asunto(s)
Conflicto de Intereses/economía , Industria Farmacéutica/economía , Hipertensión/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Sociedades Científicas/economía , Antihipertensivos/normas , Antihipertensivos/uso terapéutico , Revelación/ética , Revelación/estadística & datos numéricos , Industria Farmacéutica/ética , Industria Farmacéutica/estadística & datos numéricos , Humanos , Japón , Sesgo de Publicación , Estudios Retrospectivos , Sociedades Científicas/ética , Sociedades Científicas/normas
5.
Cuad. bioét ; 31(103): 423-427, sept.-dic. 2020.
Artículo en Español | IBECS | ID: ibc-200031

RESUMEN

La interacción entre los médicos y las compañías farmacéuticas ha sido y es habitual, se produce de múltiples formas y ha demostrado, en muchos casos, ser necesaria para el desarrollo de la medicina. Sin embargo, algunas de las técnicas de venta de la industria farmacéutica no son éticamente admisibles y pueden comprometer la independencia de los médicos. Se plantea un dilema ético a partir de un caso real en el que la búsqueda de la vulnerabilidad en la prescripción a partir de una donación por parte de una compañía farmacéutica no fue fácil de identificar


The interaction between doctors and pharmaceutical companies has been and is common, occurs in multiple ways and has proven, in many cases, to be necessary for the development of medicine. However, some of the sales techniques of the pharmaceutical industry are not ethically acceptable and can compromise the independence of physicians. An ethical dilemma arises from a real case in which the search for vulnerability in prescription based on a donation by a pharmaceutical company was not easy to identify


Asunto(s)
Humanos , Donaciones/ética , Industria Farmacéutica/ética , Prescripciones de Medicamentos , Ética Médica , Publicidad de Medicamentos , Conflicto de Intereses , Médicos/ética , Instituciones de Salud/ética
10.
PLoS One ; 15(10): e0239610, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33048952

RESUMEN

Clinical Practice Guidelines (CPGs) play significant roles in most medical fields. However, little is known about the extent of financial Conflicts of Interest (FCOIs) related to pharmaceutical companies (Pharma) selling dermatology prescription products and dermatology CPG authors in Japan. The aims of this study were to elucidate the characteristics and distribution of payments from Pharma to dermatology CPG authors in Japan, and to evaluate the extent of transparency and accuracy in their FCOI disclosures. We analyzed the records of 296 authors from 32 dermatology CPGs published by the Japanese Dermatological Association from the beginning of 2015 to the end of 2018. Using the payment data reported by 79 Pharma between 2016-2017 in Japan, we investigated the characteristics of the CPG authors and the payments from the Pharma to them. Furthermore, we evaluated the transparency and accuracy of the FCOI disclosures of the individual CPG authors. Of the 296 CPGs authors, 269 authors (90.6%) received at least one payment from the Pharma. The total monetary value of payments for the 2-year period was $7,128,762. The median and mean monetary value of payments from the Pharma reporting were $10,281 (interquartile range $2,796 -$34,962) and $26,600 (standard deviation $40,950) for the two years combined. Of the 26 CPG authors who disclosed FCOIs due to the monies received from Pharma, only the atopic dermatitis CPG authors and the acne vulgaris CPG authors published their potential FCOIs. In Japan, most dermatology CPG authors received financial payments from Pharma. The transparency of the CPGs, as reported by the CPG authors, was inadequate, and a more rigorous framework of reporting and monitoring FCOI disclosure is required to improve the accuracy and transparency with relation to possible Conflicts of Interest.


Asunto(s)
Conflicto de Intereses/economía , Dermatología/economía , Revelación , Industria Farmacéutica/economía , Guías de Práctica Clínica como Asunto , Autoria , Dermatología/ética , Revelación/ética , Industria Farmacéutica/ética , Femenino , Apoyo Financiero/ética , Humanos , Japón , Masculino , Preparaciones Farmacéuticas/economía , Sociedades Médicas/economía , Sociedades Médicas/ética
18.
Aust J Gen Pract ; 49(3): 151-154, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-32113215

RESUMEN

BACKGROUND AND OBJECTIVES: Pharmaceutical industry interactions with professional medical associations have come under scrutiny, yet industry ties among the leadership of these associations are often overlooked. The aim of this study was to investigate pharmaceutical industry payments to leaders of Australian diabetes or cardiovascular associations, and general associations serving doctors who manage these conditions. METHOD: Payments were identified using publicly available industry transparency reports (October 2015 to April 2018). RESULTS: Overall, 48/197 (24.4%) leaders received payments, predominantly for speaker (51.4%) and advisory board (25.3%) engagements. The proportion of paid leaders was higher for diabetes- and cardiovascular-specific associations (72.7% and 41.2%, respectively) than for general associations (7.6%). DISCUSSION: These findings raise concerns about industry influence on clinical practice and policy.


Asunto(s)
Conflicto de Intereses/economía , Industria Farmacéutica/ética , Sociedades/ética , Australia , Enfermedades Cardiovasculares/tratamiento farmacológico , Diabetes Mellitus/tratamiento farmacológico , Industria Farmacéutica/economía , Industria Farmacéutica/tendencias , Humanos , Sociedades/economía , Sociedades/tendencias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...